The company said that its clinical research organization Veristat completed the trial and was able to capture all patient data from 360 participants across 40 clinical sites.
Toronto-based Antibe’s original timeline to release results was impacted by the ongoing coronavirus (COVID-19) pandemic that caused governments and healthcare providers to impose hospital restrictions and clinic closures.
READ: Echelon rates Antibe Therapeutics as 'top pick' as investors eagerly await Phase II data from ATB-346 study
The restrictions, coupled with work-from-home constraints, slowed Veristat’s data collection, validation and analysis beyond the original timeframe, Antibe told shareholders.
“Although the world is facing singular challenges in light of the COVID-19 health crisis, we are fortunate to have successfully completed the collection of data for every patient enrolled in the study,” Antibe CEO Dan Legault said in a statement.
“Validating and processing these data is a non-trivial task in the current environment, especially given the study’s large number of sites. Although later than anticipated, we look forward to delivering robust and complete top-line data as soon as possible.”
ATB-346 is being developed to work as an alternative to nonsteroidal anti-inflammatory drugs, or NSAIDs. The current Phase 2 trial is designed to validate ATB-346’s effectiveness compared to placebo in reducing osteoarthritis pain.
Antibe also said its cash balance of C$6 million was sufficient to see the company through the upcoming data readout and beyond.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas